

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 September 2022 (01.09.2022)



(10) International Publication Number
WO 2022/182768 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) *A61K 31/573* (2006.01)
A61K 31/713 (2006.01) *A61P 27/06* (2006.01)

(21) International Application Number:

PCT/US2022/017533

(22) International Filing Date:

23 February 2022 (23.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/154,576	26 February 2021 (26.02.2021)	US
63/171,218	06 April 2021 (06.04.2021)	US
63/251,175	01 October 2021 (01.10.2021)	US
63/287,187	08 December 2021 (08.12.2021)	US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **PATEL, Gaurang**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HU, Ying**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **PRAVEEN, Kavita**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **COPPOLA, Giovanni**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ABECASIS, Goncalo**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **BARAS, Aris**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **ROMANO, Carmelo**; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **LEGAARD, Paul K.**; Stradley Ronon Stevens & Young, LLP, 30 Valley Stream Parkway, Malvern, Pennsylvania 19355-1481 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: TREATMENT OF INFLAMMATION WITH GLUCOCORTICOIDS AND ANGIOPOIETIN-LIKE 7 (ANGPTL7) INHIBITORS

(57) Abstract: The present disclosure provides methods of treating subjects having inflammation with an Angiotensin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.

WO 2022/182768 A1